Antonio Llombart‐Cussac

Author

Also Known As

A Cussac, A LLOMBART, A LLombart-Cussac, A Llombart, A Llombart-Cussac, A. Cussac, A. Llombart, A. Llombart Cussac, A. Llombart, Jr., A. Llombart-Cusac

700

Publications

16K

Citations

H-Index

Concepts

All Affiliations

Hospital Arnau de Vilanova Fundación Instituto Valenciano de Oncología Vall d'Hebron Institute of Oncology Hospital Clínico Universitario de Valencia MedSIR (Spain)

About

Antonio Llombart‐Cussac is an author at Hospital Arnau de Vilanova specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	65	5.7K
2	Health Sciences	12	14	346
3	Engineering	2	2	72
4	Language Studies	1	1	20
5	Management	1	1	14

Antonio Llombart‐Cussac

137

Publications

12.5K

Citations

H-Index

Page 1

	Year	Citations
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy George W. Sledge, Masakazu Toi, Patrick Neven, Journal of Clinical Oncology Breast OncologyCancer ManagementGynecologyPharmacotherapyPurpose Monarch 2	2017	1.6K
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 George W. Sledge, Masakazu Toi, Patrick Neven, JAMA Oncology	2019	941
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study W. Eiermann, Stefan Paepke, Justus Appfelstaedt, Annals of Oncology Surgical OncologyBreast OncologyPreoperative TreatmentMedicineCancer Management	2001	712
Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial Mitch Dowsett, Craig Allred, Jill Knox, Journal of Clinical Oncology	2008	463
Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment Kathy S. Albain, Shona Nag, G. Calderillo-Ruiz, Journal of Clinical Oncology	2008	418
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial Antonio Llombart‐Cussac, Javier Cortés, Laia Paré, The Lancet Oncology Breast OncologyMedicinePathologyPathological Complete ResponseImmune Checkpoint Inhibitor	2017	329
Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study J.F.R. Robertson, Antonio Llombart‐Cussac, Janusz Rolski, Journal of Clinical Oncology	2009	311
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study Holger Eidtmann, Richard de Boer, Nigel Bundred, Annals of Oncology Zoledronic AcidBreast OncologyMedicineCancer ManagementGynecology	2010	278
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez, Neuro-Oncology	2022	237
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study Matthew J. Ellis, Antonio Llombart‐Cussac, David Feltl, Journal of Clinical Oncology	2015	233

Page 1